Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease

Molecular Carcinogenesis

Volumn 50, Issue 3, 2011, Pages 153-162

  Grau, Elena ^a,b   Martinez, Francisco ^a   Orellana, Carmen ^a   Canete, Adela ^a   Yanez, Yania ^a   Oltra, Silvestre ^a   Noguera, Rosa ^a   Hernandez, Miguel ^c   Bermudez, Jose D ^c   Castel, Victoria ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CELL PROTEIN; GLUTATHIONE TRANSFERASE P1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BLU; PROTEIN CASP8; PROTEIN CCND2; PROTEIN CD44; PROTEIN DR4; PROTEIN EMP3; PROTEIN KINASE SYK; PROTEIN MLH1; PROTEIN NORE1A; PROTEIN RARB2; PROTEIN RIZ1; PROTEIN THBS1; PROTEIN TMS1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; DNA METHYLATION; EPIGENETICS; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS;

APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASE 8; CHILD; CHILD, PRESCHOOL; CYTOSKELETAL PROTEINS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 79951840043     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20700     Document Type: Article

References (40)

1. Schwab MF, Westermann Hero B, Berthold F. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-480.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120.
3. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6: 1874-1881.
4. Kaneko Y, Kanda N, Maseki N, et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 1987; 47: 311-318.
5. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the Nmyc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
6. Christiansen H, Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988; 57: 121-126.
7. Attiyeh EF, London WB, Mossé YP, et al. Children's Oncology Group, chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-2253.
8. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995; 24: 215-221.
9. Zhu J, Yao X. Use of DNA methylation for cancer detection and molecular classification. J Biochem Mol Biol 2007; 40: 135-141.
10. Hoebeeck J, Michels E, Pattyn F, et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 2009; 273: 336-346.
11. Noguera R, Canete A, Pellin A, et al. MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet 2003; 140: 157-161.
12. Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003; 21: 2077-2084.
13. Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío IJ, Castresana JS. Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet 2007; 174: 1-8.
14. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004; 96: 1208-1219.
15. Gonzalez-Gomez P, Bello MJ, Lomas J, et al. Aberrant methylation of multiple genes in neuroblastic tumours. Relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 2003; 39: 1478-1485.
16. Liu XF, Zhu SG, Zhang H, et al. The methylation status of the TMS1/ASC gene in cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat Dis Int 2006; 5: 449-453.
17. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: Prognostic importance in glioblastoma multiforme. J Neuro-Oncol 2007; 82: 133-139.
18. Zhang C, Li H, Zhou G, et al. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J Pathol 2007; 212: 134-142.
19. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535.
20. Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002; 62: 5897-5901.
21. Romero ME, Fulton BK, Davis MM, et al. Caspase 8 expression in tumors specimens from 71 neuroblastoma patients. Proc Am Assoc Cancer Res 2001; 42: 1635.
22. Fulda S, Poremba C, Berwanger B, et al. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 2006; 66: 10016-10023.
23. Ricci-Vitiani L, Pedini F, Mollinari C, et al. Absence of caspase 8 and high expression of PEDprotect primitive neural cells from cell death. J Exp Med 2004; 200: 1257-1266.
24. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7: 236-244.
25. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18: 18-26.
26. Ivanova T, Petrenko A, Gritsko T, et al. Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer 2002; 21: 2-4.
27. Arapshian A, Kuppumbatti YS, Mira-y-Lopez R. Methylation of conserved CpG cites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene 2000; 19: 4066-4070.
28. Yan P, Muhlethaler A, Bourloud KB, Beck MN, Gross N. Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Genes Chromosomes Cancer 2003; 36: 129-138.
29. Taran K, Kobos J, Sitkiewicz A, Sporny S. Estimation of prognostic value of CD44 expression in neuroblastic tumours in children. Folia Neuropathol 2007; 45: 126-132.
30. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691-699.
31. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21: 4345-4349.
32. Agathanggelou A, Bièche I, Ahmed-Choudhury J, et al. Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res 2003; 63: 5344-5451.
33. Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC. Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008; 50: 29-32.
34. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumorangiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89: 219-227.
35. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994; 59: 191-195.
36. Yang QW, Liu S, Tian Y, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003; 63: 6299-6310.
37. Teitz T, Wei T, Liu D, et al. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 2002; 21: 1848-1858.
38. Soengas MS, Gerald WL, Cordon-Cardo C, Lazebnik Y, Lowe SW. Apaf-1 expression in malignant melanoma. Cell Death Differ 2006; 13: 352-353.
39. Fulda S, Debatin KM. Apoptosis pathways in neuroblastoma therapy. Cancer Lett 2003; 197: 131-135.
40. Pritchard J, Hickman J. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994; 344: 869-870.